

## Herantis Pharma: Invitation to 1H 2023 report webinar on August 24, 2023

Herantis Pharma Plc, Press Release, August 14 2023, at 13:00 EEST

**Herantis Pharma Plc (“Herantis”)**, a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease, today announced that the company will release 1H 2023 Report on Thursday, August 24, 2023, at 08:00 EEST/ 07:00 CEST.

Members of the Herantis’ Management team will hold a live webinar to provide more details on the 1H 2023 Report with a live Q&A session (in English) for investors, analysts, and media at 10:00 EEST / 9:00 CEST on the same date.

Please join the webinar a few minutes in advance.

**Registration details:** [Herantis’ 1H 2023 Report Webinar](#)

Registration is required for this event. To register for this event, you need a Zoom account. After registering, you will receive a confirmation email containing information about joining the webinar.

Questions can be submitted throughout the webcast event.

Following the webcast of the live call, a recording will be available on Herantis Pharma’s website: <https://herantis.com/news-events/video-presentations/>

### **For more information, please contact:**

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: [ir@herantis.com](mailto:ir@herantis.com)

**Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225**

Company website: [www.herantis.com](http://www.herantis.com)

### **About Herantis Pharma Plc**

Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected by the end of 2023.

The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.

For more information, please visit <https://www.herantis.com>

